Pyrimidinones
This graph shows the total number of publications written about "Pyrimidinones" by people in the URMC Research Network by year, and whether "Pyrimidinones" was a major or minor topic of these publication.
Below are the most recent publications written about "Pyrimidinones" by people in Profiles.
-
Vogler MA, Patterson K, Kamemoto L, Park JG, Watts H, Aweeka F, Klingman KL, Cohn SE. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. J Acquir Immune Defic Syndr. 2010 Dec; 55(4):473-82.
-
Johnson MD, O'Connell M, Pilcher W. Lopinavir inhibits meningioma cell proliferation by Akt independent mechanism. J Neurooncol. 2011 Feb; 101(3):441-8.
-
DiCenzo R, DiFrancesco R, Cruttenden K, Donnelly J, Schifitto G. Lopinavir cerebrospinal fluid steady-state trough concentrations in HIV-infected adults. Ann Pharmacother. 2009 Dec; 43(12):1972-7.
-
Spitale RC, Torelli AT, Krucinska J, Bandarian V, Wedekind JE. The structural basis for recognition of the PreQ0 metabolite by an unusually small riboswitch aptamer domain. J Biol Chem. 2009 Apr 24; 284(17):11012-6.
-
Higgins N, Zingman BS, Slish J, Reichman RC, Fischl MA, Gripshover B, Tooley K, Boston N, Forrest A, Brazeau D, Catanzaro LM, DiFrancesco R, Lliguicota F, Ma Q, Morse GD. Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir. Am J Addict. 2007 Nov-Dec; 16(6):488-94.
-
Slish J, Ma Q, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Forrest A, Brazeau D, Boston NS, Catanzaro L, DiFrancesco R, Morse GD. Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring. Ther Drug Monit. 2007 Oct; 29(5):560-5.
-
DiFrancesco R, DiCenzo R, Vicente G, Donnelly J, Martin TM, Colon LA, Schifito G, Morse GD. Determination of lopinavir cerebral spinal fluid and plasma ultrafiltrate concentrations by liquid chromatography coupled to tandem mass spectrometry. J Pharm Biomed Anal. 2007 Sep 3; 44(5):1139-46.
-
Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forrest A, Morse GD. Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics. 2007 Mar; 8(3):227-35.
-
Keil K, Hochreitter J, DiFrancesco R, Zingman BS, Reichman RC, Fischl MA, Gripshover B, Morse GD. Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application. Ther Drug Monit. 2007 Feb; 29(1):103-9.
-
Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007 Jan 30; 21(3):325-33.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
|
